Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses - Scorecard - MDSpire

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses

  • By

  • Debra Nana Yeboa

  • Benjamin T. Whitfield

  • Ruitao Lin

  • Chinenye Lynette Ejezie

  • Todd A. Swanson

  • Thomas H. Beckham

  • Chenyang Wang

  • Brian De

  • Subha Perni

  • Martin C. Tom

  • Jing Li

  • Susan L. McGovern

  • Rebecca Harrison

  • Nazanin K. Majd

  • Vinay K. Puduvalli

  • Ashley E. Aaroe

  • Monica Loghin

  • Barbara J. O’Brien

  • Anuj D. Patel

  • Chirag B. Patel

  • Jeffrey S. Wefel

  • Ceylan Altintas Taslicay

  • Maria Gule-Monroe

  • Arnold C. Paulino

  • Mary Frances McAleer

  • David R. Grosshans

  • Amol J. Ghia

  • Wen Jiang

  • Caroline Chung

  • Moshe Maor

  • Cheng-Han Yang

  • Maria A. Gubbiotti

  • Carlos Kamiya-Matsuoka

  • Leomar Y. Ballester

  • Shiao-Pei Weathers

  • Jason T. Huse

  • November 5, 2025

  • 0 min

Share

Clinical Scorecard: Exploratory Analyses from a Prospective Phase II Trial of Molecular Glioblastoma (Historical Grade 2 and 3 IDH Wildtype Gliomas)

At a Glance

CategoryDetail
ConditionMolecular glioblastoma (molGBM), a subset of IDH-wildtype gliomas lacking classic histopathological features of WHO grade 4 GBM
Key MechanismsIDH-wildtype status, absence of microvascular proliferation and necrosis, DNA methylation-based stratification
Target PopulationAdult patients (≥18 years) with molecular glioblastoma previously classified as WHO grade 2 or 3 IDH-wildtype gliomas
Care SettingSpecialized neuro-oncology centers with capability for advanced radiotherapy and molecular diagnostics

Key Highlights

  • molGBM exhibits distinct imaging features with minimal-to-no contrast enhancement and different survival outcomes compared to histological GBM
  • Prior treatments for molGBM were less intense; this trial evaluates intensified radiotherapy with concurrent and adjuvant temozolomide
  • DNA methylation profiling is used as an exploratory biomarker to stratify molGBM and correlate with overall survival

Guideline-Based Recommendations

Diagnosis

  • Confirm IDH-wildtype status using immunohistochemistry and next-generation sequencing
  • Use DNA methylation profiling (Infinium EPIC platform) for molecular classification and risk stratification
  • Exclude patients with multicentric disease, prior metastatic disease, or prior brain tumor therapy

Management

  • Deliver radiotherapy with 60 Gy to gross tumor volume (GTV) and 50 Gy to clinical tumor volume (CTV) using tight margins (1–2 cm expansions respecting anatomical boundaries)
  • Use concurrent oral temozolomide during radiotherapy followed by adjuvant temozolomide as per physician discretion
  • Employ advanced radiotherapy techniques such as IMRT, VMAT, or proton therapy

Monitoring & Follow-up

  • Perform imaging with gadolinium-based contrast agents and FLAIR sequences to assess tumor volume and treatment response
  • Use Kaplan-Meier survival analysis and restricted mean survival time (RMST) for outcome evaluation
  • Monitor Karnofsky performance status (KPS) to ensure patient suitability for therapy

Risks

  • Potential for radiation-related toxicity due to dose escalation
  • Uncertainty in long-term outcomes due to molecular heterogeneity within molGBM
  • Limited data on optimal radiation volume and chemotherapy sequencing

Patient & Prescribing Data

Adults with molecular glioblastoma (IDH-wildtype, WHO grade 2 or 3 histology) with KPS ≥70

Dose escalation to 60 Gy with concurrent and adjuvant temozolomide is feasible; tighter radiotherapy margins may reduce toxicity while maintaining efficacy; molecular profiling aids in risk stratification

Clinical Best Practices

  • Incorporate molecular diagnostics including IDH status and DNA methylation profiling for accurate classification
  • Apply radiotherapy planning with precise GTV and CTV delineation using FLAIR and contrast imaging
  • Use concurrent and adjuvant temozolomide to intensify treatment in molGBM patients
  • Respect anatomical boundaries when expanding treatment volumes to minimize normal tissue exposure
  • Engage in prospective clinical trials to refine standard-of-care for molGBM subtypes

References

Original Source(s)

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses

  • by Debra Nana Yeboa, Benjamin T. Whitfield, Ruitao Lin, Chinenye Lynette Ejezie, Todd A. Swanson, Thomas H. Beckham, Chenyang Wang, Brian De, Subha Perni, Martin C. Tom, Jing Li, Susan L. McGovern, Rebecca Harrison, Nazanin K. Majd, Vinay K. Puduvalli, Ashley E. Aaroe, Monica Loghin, Barbara J. O’Brien, Anuj D. Patel, Chirag B. Patel, Jeffrey S. Wefel, Ceylan Altintas Taslicay, Maria Gule-Monroe, Arnold C. Paulino, Mary Frances McAleer, David R. Grosshans, Amol J. Ghia, Wen Jiang, Caroline Chung, Moshe Maor, Cheng-Han Yang, Maria A. Gubbiotti, Carlos Kamiya-Matsuoka, Leomar Y. Ballester, Shiao-Pei Weathers, Jason T. Huse

  • November 5, 2025

Related Content

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer